Slightly less than in 2018, approximately 8.5 million people signed up to obtain health insurance for 2019 through the ACA marketplace exchange. Here are five things that may or may not have affected these numbers.
Approximately 8.5 million people signed up to obtain health insurance for 2019 through the ACA marketplace exchange. This was slightly less than the 8.8 million individuals who signed up in 2018. The numbers were preliminary, however, and don’t represent final enrollment figures, CMS stated in a press release.
“This administration has taken strong steps to promote a more competitive, stable health insurance market and these steady enrollment numbers are yet another sign that the administration’s efforts are working,” says CMS Administrator Seema Verma. “With the lowest unemployment rate in 50 years, it’s possible that more Americans have employer-based coverage, and don’t need exchange plans.”
Here are five things health execs should know about ACA enrollment for 2019, and what actions may or may not have affected it.
The administration allowed short-term, three-month healthcare plans to be extended to a full year and renewed up to three years, although many states have their own restrictions on these plans. “By allowing lower cost alternatives, regardless of the coverage they provide, these plans will certainly siphon off consumers,” De La Torre says.
Related: How to Successfully Transition to Value-Based Care
Karen Appold is a medical writer in Lehigh Valley, Pennsylvania.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More